Liangqing Dong

Liangqing Dong

Auto-generated profile, based on publicly available information

Liangqing Dong

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Cancer Cell
Verified
Journal Article
Closed access
LDLiangqing Dong
Liangqing Dong
DLDayun Lu
Dayun Lu
RCRan Chen
Ran Chen
YLYoupei Lin
Youpei Lin
HZHongwen Zhu
Hongwen Zhu
JFJia Fan
Jia Fan

19 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYoupei Lin
Youpei Lin
LPLihua Peng
Lihua Peng
LDLiangqing Dong
Liangqing Dong
DLDongbing Liu
Dongbing Liu
JMJiaqiang Ma
Jiaqiang Ma
QGQiang Gao
Qiang Gao
Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA sequencing, T-cell receptor (TCR) sequencing, and multiplexed immunofluorescence on 207 tumor regions from 45 patients with iCCA. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active copy-number loss of clonal neoantigens, and heterogeneous immune infiltration played an important role in the subclonal evolution across tumor subregions. Highly infiltrated tumors were characterized by extensive immune activation and a similar TCR repertoire across tumor subregions, but counteracted with T-cell exhaustion and pervasive antigen presentation defects. Notably, FGFR2 mutations and fusions correlated with low mutation burden and reduced immune infiltration. Our work delineated the dynamic tumor–immune interactions and developed a robust classification system to divide patients with iCCA into high and low immune evasion groups with different prognoses. Significance: This study elucidates the impact of spatial immune heterogeneity upon tumor evolution of iCCA and reveals distinct immune evasion mechanisms developed in different immune microenvironments, which can be exploited for the development of personalized immunotherapy strategies. This article is highlighted in the In This Issue feature, p. 2221

24 July 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
KRAS mutations are causally linked to protumor inflammation and are identified as driving factors in tumorigenesis. Here, using multiomics data gathered from a large set of patients, we showed that KRAS mutation was associated with a specific landscape of alternative mRNA splicing that connected to myeloid inflammation in intrahepatic cholangiocarcinoma (iCCA). Then, we identified a negative feedback mechanism in which the upregulation of interleukin 1 receptor antagonist (IL1RN)-201/203 due to alternative splicing confers vital anti-inflammatory effects in KRAS-mutant iCCA. In KRAS-mutant iCCA mice, both IL1RN-201/203 upregulation and anakinra treatment ignited a significant antitumor immune response by altering neutrophil recruitment and phenotypes. Furthermore, anakinra treatment synergistically enhanced anti–PD-1 therapy to activate intratumoral GZMB+ CD8+ T cells in KRAS-mutant iCCA mice. Clinically, we found that high IL1RN-201/203 levels in patients with KRAS-mutant iCCA were significantly associated with superior response to anti–PD-1 immunotherapy. Significance: This work describes a novel inflammatory checkpoint mediated by IL1RN alternative splicing variants that may serve as a promising basis to develop therapeutic options for KRAS-mutant iCCA and other cancers. This article is featured in Selected Articles from This Issue, p. 2109

8 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
JLJian Lin
Jian Lin
CSChen Sang
Chen Sang
BXBin Xiang
Bin Xiang
XSXia Shen
Xia Shen
JZJunmei Zhao
Junmei Zhao
QGQiang Gao
Qiang Gao
Metabolic reprogramming within the tumor microenvironment impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multi-omics-based metabolic subtyping in intrahepatic cholangiocarcinoma (iCCA), we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both Cyclooxygenase/Arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation-mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the tumor microenvironment. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2 in turn enhances arachidonic acid uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti-PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations.

4 April 2023
Verified
Other
Open access
YLYoupei Lin
Youpei Lin
LPLihua Peng
Lihua Peng
LDLiangqing Dong
Liangqing Dong
DLDongbing Liu
Dongbing Liu
JMJiaqiang Ma
Jiaqiang Ma
QGQiang Gao
Qiang Gao
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma

4 April 2023
Verified
Other
Open access
YLYoupei Lin
Youpei Lin
LPLihua Peng
Lihua Peng
LDLiangqing Dong
Liangqing Dong
DLDongbing Liu
Dongbing Liu
JMJiaqiang Ma
Jiaqiang Ma
QGQiang Gao
Qiang Gao
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma